Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at Wedbush from $42.00 to $43.00. They now have an "outperform" rating on the stock.
Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at HC Wainwright from $49.00 to $50.00. They now have a "buy" rating on the stock.
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Tourmaline Bio, Inc. (NASDAQ: TRML) is now covered by analysts at Wedbush. They set an "outperform" rating and a $42.00 price target on the stock.
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025